Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16748
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAyati, Narjess-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorZakavi, Seyed Rasoul-
dc.contributor.authorPathmaraj, Kunthi-
dc.contributor.authorQatawneh, Loai-
dc.contributor.authorPoon, Aurora-
dc.contributor.authorScott, Andrew M-
dc.date2017-07-20-
dc.date.accessioned2017-07-27T07:26:07Z-
dc.date.available2017-07-27T07:26:07Z-
dc.date.issued2017-07-20-
dc.identifier.citationJournal of Nuclear Medicine 2017; online first: 20 Julyen_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16748-
dc.description.abstractSynthetic somatostatin analogs have been posed as a potential source of error in somatostatin receptor imaging by interfering with tumor detection; however, experimental models and clinical studies have shown a complex mechanism of octreotide effect on tumors. This study aimed to assess whether 68Ga-DOTATATE uptake differs before and after treatment with long-acting somatostatin analogs. Methods: Thirty patients with intermediate to well differentiated neuroendocrine tumors (NET) who underwent 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography (PET/CT) scanning before and after receiving long-acting repeatable (LAR) Sandostatin were included in the study. The maximum and the mean standardized uptake values (SUVmax and SUVmean) of healthy target organs, residual primary tumor and up to five lesions with the highest SUVmax in each organ were compared before and after octreotide treatment. Results: Thirty patients (15 males) with a mean age of 64.6±13.4 years were studied. The mean time interval between the two 68Ga-DOTATATE studies was 9.6±7.2 months, and the mean time gap between the last Sandostatin LAR injection and the second 68Ga-DOTATATE study was 25.1±14.8 days. The pre-treatment mean SUVmax and SUVmean were both significantly higher in the thyroid, liver and spleen (P<0.05) than the values measured after administration of Sandostatin LAR. No significant differences were found among the uptake indices for residual primary tumor or any metastatic lesions of the liver, bone, lung or lymph nodes before and after Sandostatin LAR administration (P>0.05). Conclusion: Long-acting octreotide treatment diminished 68Ga-DOTATATE uptake in the liver, spleen, and thyroid gland but did not compromise tracer uptake in residual primary tumor and metastatic lesions. These findings have direct impact on the interpretation of 68Ga-DOTATATE PET/CT scans.en_US
dc.subjectMolecular Imagingen_US
dc.subjectNeuroendocrineen_US
dc.subjectPeptidesen_US
dc.subject68Ga-DOTATATEen_US
dc.subjectLong-acting octreotideen_US
dc.subjectNeuroendocrine tumoren_US
dc.subjectSomatostatin analogsen_US
dc.subjectSomatostatin receptor imagingen_US
dc.titleSandostatin LAR therapy differentially alters 68Ga-DOTATATE uptake in normal tissues compared to primary tumors and metastatic lesionsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Nuclear Medicineen_US
dc.identifier.affiliationMashhad University of Medical Sciences, Iran, Islamic Republic ofen_US
dc.identifier.affiliationDepartment of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationNuclear Medicine and Cyclotron Unit, King Hussein Medical Center, Jordanian Royal Medical Services,, Jordanen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28729431en_US
dc.identifier.doi10.2967/jnumed.117.192203en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-6656-295Xen_US
dc.type.austinJournal Articleen_US
local.name.researcherAyati, Narjess
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.